Alvotech (ALVO)
NASDAQ: ALVO · Real-Time Price · USD
5.29
+0.05 (0.95%)
Sep 11, 2026, 4:00 PM EDT - Market closed
Alvotech Employees
Alvotech had 1,279 employees as of December 31, 2025. The number of employees increased by 267 or 26.38% compared to the previous year.
Employees
1,279
Change (1Y)
267
Growth (1Y)
26.38%
Revenue / Employee
$386,715
Profits / Employee
-$140,414
Market Cap
1.89B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,279 | 267 | 26.38% |
| Dec 31, 2024 | 1,012 | 13 | 1.30% |
| Dec 31, 2023 | 999 | 82 | 8.94% |
| Dec 31, 2022 | 917 | 133 | 16.96% |
| Dec 31, 2021 | 784 | 88 | 12.64% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bausch Health Companies | 20,300 |
| Perrigo Company | 8,100 |
| Trulieve Cannabis | 5,000 |
| Phibro Animal Health | 2,605 |
| HUTCHMED (China) | 1,790 |
| ANI Pharmaceuticals | 970 |
| Prestige Consumer Healthcare | 890 |
| Supernus Pharmaceuticals | 778 |
ALVO News
- 12 days ago - Alvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations - GlobeNewsWire
- 16 days ago - Alvotech to present at upcoming investor conferences in September - GlobeNewsWire
- 19 days ago - Alvotech initiated with a Buy at BofA - TheFly
- 22 days ago - Alvotech enters licensing, commercialization agreement with Lotus Pharmaceutical - TheFly
- 22 days ago - Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets - GlobeNewsWire
- 23 days ago - Alvotech Earnings Call Transcript: Q2 2026 - Transcripts
- 23 days ago - Alvotech Earnings release: Q2 2026 - Filings
- 23 days ago - Alvotech Slides: Q2 2026 - Filings